Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies)

Conference Reports for NATAP

19th International Workshop on
Clinical Pharmacology of Antiviral Therapy
May 22, 2018
Baltimore, USA | Baltimore Marriott Inner Harbor


Population pharmacokinetic analysis for darunavir and tenofovir alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies)

	Reported By Jules Levin 19th International Workshop on ClinicalPharmacologyof AntiviralTherapy, 22 -24 May2018, Baltimore, Maryland, USA Ackaert O1, McDougall D2, Perez Ruixo C1, Crauwels H1 1Janssen Research and Development, Beerse, Belgium, 2Model Answers Pty Ltd., Brisbane , Australia